中国实验血液学杂志最新文献

{"title":"[Application of Third-Generation Sequencing in Clinical Detection of Difficult Blood Group Samples].","authors":"Xiao-Yan Li, Dan-Dan Chen, Qiong-Fei Deng, Xiao-Li Lai, Dan Wang, Xuan Zeng","doi":"10.19746/j.cnki.issn1009-2137.2026.04.029","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.029","url":null,"abstract":"<p><strong>Objective: </strong>To explore the value of third-generation sequencing (TGS) in resolving discrepancies between serological findings and Sanger sequencing results in difficult blood group cases.</p><p><strong>Methods: </strong>Samples were collected from 3 patients with difficult blood group typing (including family members of 2 patients) treated at our hospital between January 2023 and May 2025. Blood group identification was performed using serological testing, PCR genotyping, and first-generation (Sanger) sequencing. For cases with inconsistent serological phenotypes and genotypes, further analysis was performed using TGS to identify the underlying causes.</p><p><strong>Results: </strong>All three cases showed inconsistencies between serological and Sanger sequencing results. Case 1 showed an AB₃ serological phenotype, a genotyping result of <i>AB</i> , and Sanger sequencing identified <i>ABO*A1.02/ABO*B.01</i>. TGS revealed a promoter region mutation (-35_-18del) leading to weakened B antigen expression. Case 2 showed an A_elB serological phenotype, a genotyping result of AB, and Sanger sequencing identified <i>ABO*A1.02/ABO*B3.07</i>, which was inconsistent with the weakened A antigen expression suggested by serology. TGS demonstrated that the c.410C>T mutation was located on the A haplotype rather than the B haplotype, resulting in the A_elB phenotype. Case 3 showed a serological phenotype of RhD--, Sanger sequencing identified <i>RHCE*02/RHCE*02</i>, and TGS detected an <i>RHCE-D(2-9)-CE</i> gene recombination.</p><p><strong>Conclusion: </strong>TGS overcomes the limitations of first-generation sequencing in blood group genotyping by enabling the detection of non-coding region mutations, accurate haplotype phasing, and identification of gene recombination events.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1132-1138"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Construction and Validation of a Multivariable Nomogram Model for Survival Prediction in Patients with Multiple Myeloma].","authors":"Jun Lu, Xi-Jun Zhu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.014","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.014","url":null,"abstract":"<p><strong>Objective: </strong>To construct and validate a multivariable nomogram model for survival prediction in patients with multiple myeloma (MM) based on bone marrow flow cytometric immunophenotypes and peripheral blood inflammatory indices, so as to provide a tool for individualized prognostic assessment in clinical practice.</p><p><strong>Methods: </strong>A total of 110 newly diagnosed MM patients admitted to the Department of Hematology of Xuancheng People's Hospital from January 2020 to June 2025 were retrospectively enrolled and randomly assigned (1∶1) to a training cohort (<i>n</i>=55) and a validation cohort (<i>n</i>=55) using a random number table method. Baseline clinical data and bone marrow flow cytometric expression of CD56, CD19, CD28 and CD117 were collected. The peripheral blood neutrophil-to-lymphocyte ratio (NLR) and lymphocyte-to-monocyte ratio (LMR) were calculated. Overall survival (OS) was defined as the primary endpoint. Univariate analysis was performed using the Kaplan-Meier method and log-rank test. Independent prognostic factors were identified by multivariate Cox proportional hazards regression in the training cohort, on the basis of which a nomogram was constructed. Model performance and clinical utility were evaluated by the concordance index (C-index), receiver operating characteristic (ROC) curves, calibration curves and decision curve analysis (DCA), and externally validated in the validation cohort.</p><p><strong>Results: </strong>By the end of follow-up, the median follow-up time was 32 months, and the median OS for the whole cohort was 41.5 months. Multivariate analysis showed that CD56 negativity, CD28 positivity, high NLR and low LMR were all independent adverse prognostic factors for OS (all <i>P</i> < 0.05). The nomogram constructed on these variables yielded a C-index of 0.78 in the training cohort, with area under the curve (AUC) values of 0.82 and 0.80 for 1-year and 3-year OS prediction, respectively. In the validation cohort, the C-index was 0.76, and the AUCs for 1-year and 3-year OS were 0.79 and 0.77, respectively. Calibration curves indicated good agreement between predicted and observed survival probabilities, and DCA suggested that the model provided substantial net benefit across a wide range of threshold probabilities.</p><p><strong>Conclusion: </strong>Bone marrow plasma cell expression of CD56 and CD28, together with peripheral blood NLR and LMR, are important independent prognostic factors for survival in MM patients. The multivariable nomogram model based on these parameters shows good discrimination and calibration, and can accurately predict patient survival, thereby facilitating individualized risk stratification and treatment decision-making.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1024-1030"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070241","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Molecular Mechanism of Reduced RhCE Antigen and Precision Transfusion].","authors":"Yang Xue, Chao Li, Wen-Long Xin, Xing Zeng, Zhan-Yun Song, Hong-Jun Gao, Zheng-Ling Shang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.028","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.028","url":null,"abstract":"<p><strong>Objective: </strong>To analyze the <i>RH</i> genotype and molecular mechanisms of weakened RhCE antigens in 10 cases, and to investigate the impact of genetic variations on Rh antigen expression.</p><p><strong>Methods: </strong>A total of 10 cases with weak expression samples in Rh typing initial tests who visited Guiyang Maternal and Child Health Care Hospital from January 2023 to December 2024 were selected. Two different manufacturers' monoclonal antibodies were used for further RhCE serological typing via tube method. The human red blood cell <i>RHCE</i> blood type gene typing kit was used to detect the <i>RH</i> gene fluorescence typing of the samples. PCR technology was used to sequence the exons of the <i>RHCE</i> exons. The modeling analysis of the RhCE protein was performed using Swiss-Model. The impact of mutations on protein function was predicted using PolyPhen-2 software.</p><p><strong>Results: </strong>The serological results of RhCE in the blood samples of 10 patients showed that patients 1 to 8 had varying degrees of weakened RhC antigen expression (±～2+); patients 9 and 10 exhibited weakened expression of Rhc (1+) and Rhe (2+) antigens, respectively. The fluorescence PCR method detected <i>RHCE</i> typing, and the results of fluorescence typing were consistent with the Rh blood type serology. Sanger sequencing revealed a total of 8 variant sites, namely c.48G>C in exon 1, c.150C>T, c.178C>A, c.201A>G, c.203A>G, c.307C>T in exon 2, c.375C>G in exon 3, and c.676G>C in exon 5. According to the PolyPhen-2 platform, it is predicted that the p.Trp16Cys mutation is benign and the p.Ile125Met mutation is probably damaging.</p><p><strong>Conclusion: </strong>This study is the first to correlate homozygous c.48G>C with markedly weakened RhC expression and suggest a damaging role for p.Ile125Met in Rhe antigenicity. Genotyping clarifies the molecular basis of weak antigen expression, supporting precision transfusion medicine.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1125-1131"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Retrospective Evaluation of Transfusion Efficacy of Different Platelet Matching Methods in Patients with Platelet Transfusion Refractoriness].","authors":"Pin Yi, Ming-Ming Wang, Chang-Ru Luo, Xiao-Han Zhang, Su-Qing Gao, Chao-Peng Shao, Chang-Lin Wu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.031","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.031","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To compare and analyze the transfusion efficacy of different platelet matching methods in patients with platelet transfusion refractoriness (PTR), and to provide clinical evidence for selecting reasonable and effective platelet matching and transfusion strategies for these patients.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted on the data of 827 times of platelet matching and transfusion in 77 PTR patients in our hospital from January 2022 to October 2024. The corrected count increment (CCI) values before and after platelet transfusion based on solid-phase agglutination (SPA)-matching were analyzed in PTR patients with negative or positive results of platelet antibody screening. The transfusion efficacy of routine SPA-matching in PTR patients with different disease types was evaluated, and the platelet transfusion outcomes were compared among patients with negative, weakly positive and mildly positive results of SPA-matching. The differences in transfusion efficacy among SPA-matching, HLA antigen-matching, and HLA epitope-matching in PTR patients with positive platelet antibody screening results were comprehensively analyzed.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among 77 patients with PTR, the positive rate of platelet antibody was 54.5% (42/77). Of these, 38 patients were positive for HLA class I (HLA-I) antibodies, and 4 patients were positive for both HLA-I and HPA antibodies. The overall response rates (ORRs) of platelet transfusion based on SPA-matching in PTR patients with positive and negative platelet antibody were 54.3% (279/514) and 31.1% (64/206), respectively, and the difference was statistically significant (&lt;i&gt;P&lt;/i&gt;&lt;0.05). The ORRs of platelet transfusion in patients with negative, weakly positive (±), and mildy positive (+) SPA-matching results were 48.6% (292/601), 45.5%(30/66), and 47.2% (25/53), respectively, and there were no significant differences among them (all &lt;i&gt;P&lt;/i&gt;&gt;0.05). The main disease types of the enrolled PTR patients included leukemia, myelodysplastic syndromes (MDS), autoimmune diseases, solid tumors, and sepsis. The ORRs of platelet transfusion based on SPA-matching in these disease types were 52.9% (217/410), 19.4% (25/129), 60.0% (12/20), 42.6% (52/122), and 93.9% (31/33), respectively. Among them, patients with MDS had the lowest ORR, followed by those with solid tumors, while patients with sepsis had the highest ORR. Among the 42 PTR patients with positive platelet antibodies, 5 patients received 68 times of platelet transfusion based on HLA antigen-matching after failing to respond to transfusion based on SPA-matching, with an ORR of 75.0% (51/68). Meanwhile, 2 patients underwent 39 times of platelet transfusion based on HLA epitope-matching after ineffective transfusion based on SPA-matching, yielding an ORR of 74.4% (29/39). Comparative analysis revealed no statistically significant difference in the ORRs between platelet transfusion based on HLA antige","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1146-1152"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Retrospective Analysis and Model-Based Prediction of HIV/HBV/HCV/TP Test Results among Voluntary Blood Donors in Suzhou City].","authors":"Lu-Lu He, Ya-Qiong He, Chun-Ling Li, Ying Su, Ling-Ling Wang, Xiao-Tang Li, Yan Wang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.030","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.030","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate and predict the prevalence of HIV, HBV, HCV, and TP among voluntary blood donors in Suzhou City, and to provide a reference for developing scientific strategies for voluntary blood donation and reducing the discard of unqualified blood units.</p><p><strong>Methods: </strong>Enzyme-linked immunosorbent assay (ELISA) and nucleic acid amplification testing (NAT) were used to detect HIV, HBV, HCV, and TP in blood samples from voluntary blood donors in Suzhou City from 2021 to 2023. The demographic characteristics of donors positive for the above-mentioned pathogens were identified by univariate analysis, while exponential smoothing method was utilized to analyze the temporal trends of the HIV, HBV, HCV, and TP infections.</p><p><strong>Results: </strong>A total of 66 015 voluntary blood donors were enrolled in this study, of whom 0.91% tested positive for at least one pathogen. The positivity rates of the four pathogens ranked in descending order as follows: TP（0.38%）, HBV（0.29%）, HCV（0.18%）, and HIV（0.07%）. During the research period, the positive rates of all four pathogens showed a sustained downward trend. The overall infection rate of the four pathogens was associated with age, occupation, and education level: the highest combined positivity rates of the four pathogens were identified among individuals aged 45-60 years, farmers, and those with junior high school education or below; the lowest combined positivity rates were observed in young adults aged 18-24 years, students, and those with a bachelor's degree or above. The annual number of positive cases for the four pathogens showed periodic fluctuation with a significant seasonal pattern. Peaks tend to occur in the first quarter, while troughs tend to occur in the third quarter. The goodness-of-fit test of the simple seasonal exponential smoothing model showed that BIC, stationary R², RMSE, and MAPE were 3.106, 0.839, 4.278, and 22.264, respectively, with the Ljung-Box statistic being 22.508 (<i>P</i> >0.05). The model forecasts 193（95% <i>CI</i> ：89-297） positive blood donors for the four major pathogens in 2024, indicating a slight decrease from 2023. The positivity rates were predicted to peak in January-February and reach the nadir in July-August.</p><p><strong>Conclusion: </strong>In recent years, the overall epidemiological situation of HIV, HBV, HCV, and TP infections among voluntary blood donors in Suzhou City has shown a steady and favorable improvement. It is recommended that more targeted strategies for voluntary blood donation be formulated by combining the seasonal fluctuation trends of the four pathogens and the demographic characteristics of the positive population.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1139-1145"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070395","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Serological and Molecular Biological Analysis of 56 Cases with Weak D Antigen Expression and 14 Cases with Anti-D Pattern].","authors":"Hong-Mei Yang, Si-Fei Ma, Xin Zou, Min-Jie Chen, Li Xu, Ya-Hong Chen","doi":"10.19746/j.cnki.issn1009-2137.2026.04.032","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.032","url":null,"abstract":"<p><strong>Objective: </strong>To explore the serological weak expression of the RhD antigen in 56 samples and the serological and molecular biological characteristics of 14 samples with anti-D pattern detected by the RhD negative confirmation test, and to investigate the correlation between haplotype genotypes and RhCcEe phenotypes for accurate identification of anti-D and anti-LW.</p><p><strong>Methods: </strong>A total of 56 samples with serologically confirmed weak RhD antigen expression were selected from 169 538 blood donors, and haplotype detection was conducted using PacBio SMRT third-generation sequencing technology. For the 14 serologically confirmed RhD negative samples exhibiting anti-D pattern, absorption-elution tests, SSP-PCR (c.1227G>A), differential tests for anti-D and anti-LW antibodies, and haplotype detection were performed.</p><p><strong>Results: </strong>Ten known alleles (51/56) and 5 novel alleles (5/56) were identified. The known alleles included <i>RHD*weak partial 15</i>(20/56), <i>RHD*DVI.3</i>(14/56), <i>RHD*weak D type33</i> (5/56), <i>RHD*weak partial 15/RHD*01EL.01</i>(4/56), <i>RHD*DCS2</i> (3/56), <i>RHD*weak partial 15/RHD*01N.04</i>(1/56), <i>RHD*weak D type38</i> (1/56), <i>RHD*weak D type17</i>(1/56), <i>RHD*DV.5</i>(1/56), <i>RHD*DFR1</i>(1/56). The novel alleles consisted of <i>RHD*01N.04</i> with c.781C>G, <i>RHD*01EL.01</i> with.c.487-2A>G, <i>RHD*01N.01</i> with c.781C>G, <i>RHD*weak D33</i> with c.953G>C, <i>RHD*01N.01</i> with <i>RHD-CE(10)</i> recombination. The RhCcEe phenotypes for the 14 anti-D pattern samples were ccee (7/14), Ccee (2/14), CCee (2/14), CcEe (1/14), ccEe (1/14), and ccEE (1/14); the alleles were <i>RHD*01N.01(7/14)</i> and <i>RHD*01 EL.01(7/14)</i>.</p><p><strong>Conclusion: </strong>Through serological and molecular biology analysis, the RhD blood type was accurately detected, multiple alleles were identified. The RhCcEe phenotype and allele profiles of 14 samples with anti-D patterns were clarified, which helps to correctly identify anti-D and anti-LW.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1153-1159"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070467","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Integrative Multi-omics Analysis of the <i>Tnf-Pnpla2-Rictor-Nr1d1</i> Network Underlying the Hemostatic Action of <i>Bletilla Striata</i>].","authors":"Tao Yang, Yan Xiong, Ling Yang, Xing-Gang Wang, Yong Huang, Zhi-Li Fu","doi":"10.19746/j.cnki.issn1009-2137.2026.03.026","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.03.026","url":null,"abstract":"<p><strong>Objective: </strong>By integrating transcriptomics and network pharmacology, we systematically investigated the potential hemostatic mechanism of <i>Bletilla striata</i> (BS).</p><p><strong>Methods: </strong>Thirty SPF-grade Kunming mice were randomly divided into three groups (<i>n</i> =10 per group): Control group, Model group, and BS group. The BS group was orally administered <i>Bletilla striata</i> extract (2.48 g/kg) for 7 consecutive days, while the Control and Model groups received an equal volume of 0.5% sodium carboxymethyl cellulose (CMC-Na) solution. On day 7, the Model and BS groups were injected via the tail vein with heparin sodium (0.8 U per mouse) to inducesystemic bleeding. The bleeding time (BT) was measured by tail tip amputation, and coagulation parameters including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), and plasma fibrinogen (FIB) were measured using a semi-automaticcoagulation analyzer. Liver tissues were collected for total RNA extraction and transcriptome sequencing to identify differentially expressed genes (DEGs) related to coagulation pathways. Network pharmacology was used to construct aprotein-protein interaction (PPI) network, screen hub genes, and perform molecular docking to evaluate the binding affinity between the active component militarineand key target proteins.</p><p><strong>Results: </strong>Compared with the Model group, preventive treatment with BS significantly shortened BT and CT (<i>P</i> <0.01), and reversed coagulation parameters: APTT, PT, and TT were significantly reduced (<i>P</i> <0.01), while FIB levels were significantly elevated <i>P</i> <0.001). Transcriptome analysis showed that the hepatic gene expression profile in the BS group was closer to that of the Control group. Network pharmacologyidentified <i>Tnf, Rictor, Nrld1</i> , and <i>Pnpla2</i> askey hub genes involved in the hemostaticprocess, all of which exhibited favorable binding affinity with militarine. Compared to the control group, the Model group showed a significant decrease in hepatic <i>Tnf</i> expression but significant increases in <i>Rictor, Nr1d1</i> , and <i>Pnpla2</i>. After preventive intervention with <i>Bletilla striata</i> , the hepatic <i>Tnf</i> expression in the mice was significantly increased compared to the Model group, while <i>Rictor, Nr1d1</i> , and <i>Pnpla2</i> significantly decreased. These findings were further validated by RT-PCR and molecular docking analyses.</p><p><strong>Conclusion: </strong>This study reveals that the hemostatic effect of BS is potentially mediated through multi-target synergistic regulation of coagulation factor transcription, coupled with modulations in lipid metabolism and circadian rhythms. It provides a theoretical basis for developing novel hemostatic agents.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 3","pages":"813-821"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The Impact of CD4⁺/CD8⁺ Ratio on the Efficacy of CAR-T Therapy in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma].","authors":"Fan Xia, Qian Zhu, Jun-Hong Li, Xiao Zhang, Chang-Ju Qu, Na-Na Ping","doi":"10.19746/j.cnki.issn1009-2137.2026.03.013","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.03.013","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the predictive value of peripheral blood CD4⁺/CD8⁺ ratio immediately prior to chimeric antigen receptor T-cell (CAR-T) infusion (Day 0) for treatment efficacy in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).</p><p><strong>Methods: </strong>A retrospective analysis was conducted on data from 49 R/R DLBCL patients who received CAR-T therapy at The First Affiliated Hospital of Soochow University between January 2017 and June 2024. The relationship between the Day 0 peripheral blood CD4⁺/CD8⁺ ratio and treatment efficacy was evaluated.</p><p><strong>Results: </strong>At 3 months post-CAR-T infusion, the objective response rate of the 49 patients was 75.5% (37/49), comprising a complete response rate of 55.1% (27/49) and a partial response rate of 20.4% (10/49). Patients with a Day 0 peripheral blood CD4⁺/CD8⁺ ratio ≥1 had a significantly higher 90-day response rate than those with a ratio <1 (88.2% <i>vs.</i> 46.7%, <i>P</i> =0.002). Multivariate analysis showed that the Day 0 peripheral blood CD4⁺/CD8⁺ ratio was an independent predictor of both progression-free survival (PFS) and overall survival (OS) (<i>P</i> =0.025； <i>P</i> =0.037). Patients with a ratio ≥1 had significantly longer median PFS (11.0 <i>vs.</i> 3.0 months, <i>P</i> =0.011) and median OS (32.1 <i>vs.</i> 8.5 months, <i>P</i> =0.003) compared to those with a ratio <1.</p><p><strong>Conclusion: </strong>Peripheral blood CD4⁺/CD8⁺ ratio ≥1 immediately prior to CAR-T infusion can predict a higher CAR-T treatment response rate and superior survival outcomes in R/R DLBCL patients.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 3","pages":"719-725"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664643","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Multi Model Study and Clinical Decision Analysis of Early Death Risk Warning in Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab].","authors":"Bi-Wei Wang, Hui Sun, Xi Chen, Huan Wang, Xiao-Long Li","doi":"10.19746/j.cnki.issn1009-2137.2026.03.017","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.03.017","url":null,"abstract":"<p><strong>Objective: </strong>To retrospectively analyze the early death of patients with newly diagnosed multiple myeloma (NDMM) treated with daratumumab, build a risk warning model and verify its clinical decision-making benefits.</p><p><strong>Methods: </strong>The clinical data of 112 NDMM patients treated with daratumumab combination therapy in Tangshan Gongren Hospital from June 2018 to June 2022 were retrospectively collected as the training set, and the clinical data of 78 NDMM patients who received daratumumab combination therapy in the same period were collected as the validation set. According to whether early death occurred during regular follow-up (OS <24 months), the patients were divided into early death group (26 cases) and non-early death group (86 cases). The differences of clinical data between the two groups were analyzed, and Kaplan-Meier survival curves were used to analyze the survival difference of patients with different efficacy. Univariate and multivariate Cox regression analysis were used to analyze the independent risk factors affecting early death of NDMM patients treated with daratumumab. A warning nomogram model for the risk of early death was established, and the predictive performance was analyzed by receiver operating characteristic (ROC) curve and verified internally.</p><p><strong>Results: </strong>According to whether the efficacy of daratumumab treatment achieved partial response (PR), the patients were divided into <PR group (32 cases) and ≥PR group (80 cases). Kaplan-Meier analysis found that the median OS of both groups were not reached, while the OS of patients with efficacy ≥PR was significantly longer than that of patients with efficacy <PR (log-rank <i>χ</i>²=14.225, <i>P</i> <0.001). Multivariate Cox regression analysis showed that older age, R-ISS stage Ⅲ, elevated hs-CRP, and efficacy <PR were independent risk factors for early death in NDMM patients (all <i>P</i> <0.05), and a nomogram model for early death risk in NDMM patients was constructed. ROC analysis and DeLong test showed that the AUC of the nomogram model was 0.894(95%<i>CI</i> : 0.828-0.959), which was higher than that of each individual model, and the differences were statistically significant (all <i>P</i> <0.05). Internal and external validation showed that the nomogram model was stable and had a positive net benefit.</p><p><strong>Conclusion: </strong>The OS of NDMM patients who did not reach PR after daratumumab treatment can be affected. Daratumumab treatment early death risk warning model for NDMM has good efficacy, and can be targeted at high-risk population for intensive treatment to improve prognosis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 3","pages":"744-753"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Cellular Senescence in Hematological Malignancies: Pathogenesis and Traditional Chinese Medicine Treatment Strategies--Review].","authors":"Ming-Yi Wang, Xue-Jun Zhu","doi":"10.19746/j.cnki.issn1009-2137.2026.03.041","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.03.041","url":null,"abstract":"<p><p>Cellular senescence is fundamentally characterized as an irreversible cell cycle arrest state. Studies have revealed that cellular senescence plays a significant role in the pathogenesis and progression of hematological malignancies. Consequently, inducing cellular senescence has emerged as a therapeutic strategy for these malignancies. Traditional Chinese herbal medicine, characterized by its high efficacy and relatively low toxicity, has shown unique potential in inducing senescence in hematological tumor cells. Previous studies have shown that traditional Chinese herbal medicine can induce cellular senescence through mechanisms such as telomere shortening, DNA damage induction, and regulation of the senescence-associated secretory phenotype (SASP) to treat hematological malignancies. This review aims to summarize the recent advances in the mechanisms by which cellular senescence contributes to the pathogenesis of hematological malignancies and the role of traditional Chinese herbal medicine in inducing cellular senescence for therapeutic purposes, thereby providing novel insights and theoretical support for the application of traditional Chinese herbal medicine in the treatment of hematological malignancies.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 3","pages":"917-921"},"PeriodicalIF":0.0,"publicationDate":"2026-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664479","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}